You are here: Industry Insights > Boehringer Ingelheim

News List

Boehringer Ingelheim’s latest COPD campaign centers on 'inhaleability' fiercepharma
August 08, 2019
Taking a deep breath can be hard for COPD patients. The irony is, that's exactly what they often need to do to release their medicine from inhalers.
Boehringer Ingelheim Acquires AMAL Therapeutics americanpharmaceuticalreview
July 16, 2019
Boehringer Ingelheim announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and ...
BI announces Dabigatran's safety and efficacy for management of VTE in children biospectrumasia
July 10, 2019
Pradaxa is not approved in any country for paediatric patients with VTE.
Boehringer Ingelheim inks $870M worth deal with Yuhan Corp biospectrumasia
July 04, 2019
Boehringer Ingelheim and Yuhan Corporation have announced a collaboration and license agreement for the development of a first-in-class dual agonist for the treatment of NASH and related liver diseases that combines GLP-1 and FGF21 activity in one molecul
The healthcare of tomorrow: Boehringer Ingelheim relies on digital transformation firstwordpharma
June 12, 2019
Digitalization is changing the healthcare system: Digital technologies are opening up new opportunities in the development of innovative medications and the healthcare solutions of tomorrow.
Boehringer Ingelheim, Gubra collaborate for the development of anti-obesity peptide poly-agonists biospectrumasia
June 05, 2019
Gubra may receive up to EUR 240 million in upfront and success-based development and commercialization milestones plus staggered up to double-digit royalties on worldwide net sales
Boehringer Ingelheim increases focus on Chinese rural areas biospectrumasia
April 23, 2019
German pharmaceutical company Boehringer Ingelheim is increasingly focusing on the rural areas of China, which generated almost 30 per cent of its net sales, taking the total net sales in China in 2018 to 658 million euros.
Boehringer Ingelheim increases focus on Chinese rural areas biospectrumasia
April 23, 2019
German pharmaceutical company Boehringer Ingelheim is increasingly focusing on the rural areas of China, which generated almost 30 per cent of its net sales, taking the total net sales in China in 2018 to 658 million euros.
PureTech Health, Boehringer Ingelheim enter $26M immuno-oncology deal pharmatimes
April 21, 2019
PureTech Health has announced a collaboration with Boehringer Ingelheim to advance immuno-oncology product candidates, using its lymphatic targeting platform.
PureTech Health Announces Collaboration with Boehringer Ingelheim pharmafocusasia
April 19, 2019
PureTech Health Announces Collaboration with Boehringer Ingelheim

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page